TAMI Trial

Toxtyper analysis in young patients with Acute Myocardial Infarction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28415

Enrollment

200

Registered

2019-10-24

Start date

2020-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

none

Eligibility

Inclusion criteria

Inclusion criteria: • Age >17 and <46 years old • Diagnosed with AMI according to ESC protocol

Exclusion criteria

Exclusion criteria: • Start of symptoms of ACS >48hr prior to inclusion • No informed consent obtained

Design outcomes

Primary

Measure	Time frame
To investigate the incidence of DOA use in patients between 18 and 45 years old presenting at the emergency department (ED or coronary care unit (CCU) at the participating hospitals with AMI.	—

Secondary

Measure	Time frame
-To evaluate which DOA are prevalent in young patients with AMI -To investigate the difference in other cardiac risk-factors and risk-stratification scores in the DOA versus no-DOA group -To investigate the difference in significant atherosclerotic CAD in the DOA versus no-DOA group -To investigate the difference in length of hospital stay in the DOA versus no-DOA group -To investigate the difference in major adverse cardiac events (MACE) in the DOA versus no-DOA group	—

Measure

Time frame

-To evaluate which DOA are prevalent in young patients with AMI -To investigate the difference in other cardiac risk-factors and risk-stratification scores in the DOA versus no-DOA group -To investigate the difference in significant atherosclerotic CAD in the DOA versus no-DOA group -To investigate the difference in length of hospital stay in the DOA versus no-DOA group -To investigate the difference in major adverse cardiac events (MACE) in the DOA versus no-DOA group

—

Contacts

Public ContactFemke Gresnigt

OLVG

f.m.j.gresnigt@olvg.nl0205999111 sein 4226

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)